triiodothyronine has been researched along with Carcinoma, Papillary, Follicular in 6 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Carcinoma, Papillary, Follicular: A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate cardiovascular functionality in patients with thyroid cancer, we have performed echocardiography and ambulatory blood pressure monitoring in 19 women with differentiated thyroid carcinoma during thyroxine withdrawal, at three time points: the last day on TSH-suppressive thyroxine doses (subclinical or mild hyperthyroidism), 4-7 days after withdrawal (normal free thyroxine (FT4) and free triiodothyronine (FT3) levels), and before 131I whole body scanning (overt hypothyroidism)." | 7.72 | Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. ( Barrios, V; Botella-Carretero, JI; Caballero, C; Escobar-Morreale, HF; García-Robles, R; Gómez-Bueno, M; Sancho, J, 2004) |
| "To evaluate cardiovascular functionality in patients with thyroid cancer, we have performed echocardiography and ambulatory blood pressure monitoring in 19 women with differentiated thyroid carcinoma during thyroxine withdrawal, at three time points: the last day on TSH-suppressive thyroxine doses (subclinical or mild hyperthyroidism), 4-7 days after withdrawal (normal free thyroxine (FT4) and free triiodothyronine (FT3) levels), and before 131I whole body scanning (overt hypothyroidism)." | 3.72 | Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. ( Barrios, V; Botella-Carretero, JI; Caballero, C; Escobar-Morreale, HF; García-Robles, R; Gómez-Bueno, M; Sancho, J, 2004) |
| "The prevalence of Hashimoto thyroiditis and NHLT in the 560 papillary thyroid cancer (PTC) patients was found to be 7." | 1.38 | Diagnostic value of antithyroid peroxidase antibody for incidental autoimmune thyroiditis based on histopathologic results. ( Hong, HP; Jung, SJ; Kang, T; Kim, DW; Kim, YW; Kwon, MJ; Park, YM; Rho, MH, 2012) |
| " After complete thyroidectomy and substitution with levothyroxine (l-T(4)), the preoperative, inadequately low T(4) and free T(4) remained, while increasing the l-T(4) dosage led to T(3) serum concentrations above the normal range." | 1.37 | Monocarboxylate transporter 8 deficiency: altered thyroid morphology and persistent high triiodothyronine/thyroxine ratio after thyroidectomy. ( Chiu-Ugalde, J; de Angelis, MH; Grüters, A; Klein, MO; Köhrle, J; Krude, H; Mossbrugger, I; Quintanilla-Martinez, L; Riebel, T; Rothe, K; Sapin, R; Schmid, KW; Schweizer, U; Sheu, SY; Wirth, EK, 2011) |
| "Insulin resistance is closely related to post-THW hypothyroidism in patients of DTC." | 1.35 | Factors related to clinical hypothyroid severity in thyroid cancer patients after thyroid hormone withdrawal. ( Chang, WD; Huang, SC; Lin, SY; Lin, YH; Sheu, WH; Song, YM; Wu, CC; Wu, VC, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, SC | 1 |
| Wu, VC | 1 |
| Lin, SY | 1 |
| Sheu, WH | 1 |
| Song, YM | 1 |
| Lin, YH | 1 |
| Wu, CC | 1 |
| Chang, WD | 1 |
| Emmanouilidis, N | 1 |
| Müller, JA | 1 |
| Jäger, MD | 1 |
| Kaaden, S | 1 |
| Helfritz, FA | 1 |
| Güner, Z | 1 |
| Kespohl, H | 1 |
| Knitsch, W | 1 |
| Knapp, WH | 1 |
| Klempnauer, J | 1 |
| Scheumann, GF | 1 |
| Wirth, EK | 1 |
| Sheu, SY | 1 |
| Chiu-Ugalde, J | 1 |
| Sapin, R | 1 |
| Klein, MO | 1 |
| Mossbrugger, I | 1 |
| Quintanilla-Martinez, L | 1 |
| de Angelis, MH | 1 |
| Krude, H | 1 |
| Riebel, T | 1 |
| Rothe, K | 1 |
| Köhrle, J | 1 |
| Schmid, KW | 1 |
| Schweizer, U | 1 |
| Grüters, A | 1 |
| Rho, MH | 1 |
| Kim, DW | 1 |
| Hong, HP | 1 |
| Park, YM | 1 |
| Kwon, MJ | 1 |
| Jung, SJ | 1 |
| Kim, YW | 1 |
| Kang, T | 1 |
| Botella-Carretero, JI | 1 |
| Gómez-Bueno, M | 1 |
| Barrios, V | 1 |
| Caballero, C | 1 |
| García-Robles, R | 1 |
| Sancho, J | 1 |
| Escobar-Morreale, HF | 1 |
| Taniyama, M | 1 |
| Ishikawa, N | 1 |
| Momotani, N | 1 |
| Ito, K | 1 |
| Ban, Y | 1 |
1 trial available for triiodothyronine and Carcinoma, Papillary, Follicular
| Article | Year |
|---|---|
Surgery and radioablation therapy combined: introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH.
Topics: Adult; Carcinoma, Papillary, Follicular; Cohort Studies; Combined Modality Therapy; Female; Humans; | 2009 |
5 other studies available for triiodothyronine and Carcinoma, Papillary, Follicular
| Article | Year |
|---|---|
Factors related to clinical hypothyroid severity in thyroid cancer patients after thyroid hormone withdrawal.
Topics: Adult; Body Mass Index; Carcinoma, Papillary, Follicular; Cholesterol; Female; Homeostasis; Humans; | 2009 |
Monocarboxylate transporter 8 deficiency: altered thyroid morphology and persistent high triiodothyronine/thyroxine ratio after thyroidectomy.
Topics: Animals; Blotting, Western; Carcinoma, Papillary, Follicular; Child; Electrophoresis, Polyacrylamide | 2011 |
Diagnostic value of antithyroid peroxidase antibody for incidental autoimmune thyroiditis based on histopathologic results.
Topics: Adult; Aged; Analysis of Variance; Antibodies; Carcinoma, Papillary, Follicular; Female; Hashimoto D | 2012 |
Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma.
Topics: Adult; Blood Pressure; Carcinoma, Papillary, Follicular; Cardiovascular Diseases; Cell Differentiati | 2004 |
Toxic multinodular goitre in a patient with generalized resistance to thyroid hormone who harbours the R429Q mutation in the thyroid hormone receptor beta gene.
Topics: Amino Acids; Biomarkers; Carcinoma, Papillary, Follicular; Female; Goiter, Nodular; Humans; Middle A | 2001 |